Standard type 2 diabetes treatments may not improve the condition in youth

The Restoring Insulin Secretion (RISE) Pediatric Medication Study.

Woman taking sample of her diabetic daughter's blood using lancet pen at home, closeup
Woman taking sample of her diabetic daughter's blood using lancet pen at home, closeup (© stock.adobe.com)

A new study by the Yale scientists, taking insulin or the most commonly used drug for type 2 diabetes, metformin, failed to either delay or effectively treat the condition in youth.

In the study, dubbed as Restoring Insulin Secretion (RISE) Pediatric Medication Study, scientists explored the impact of two medications for pre-diabetes or diabetes in youth aged 10 to 19. The children and teens either took infusions of insulin for three months, trailed by metformin for a year, or metformin alone. Amid the 15-month contemplate period, the analysts surveyed glucose levels of study members and also the capacity of their beta cells, which store and discharge insulin keeping in mind the end goal to keep up solid glucose.

Scientists discovered that the medications neglected to moderate or stop the progression of type 2 diabetes in either group. The working of the adolescents’ beta cells kept on breaking down in spite of the treatments, which have been appealed to treat write 2 diabetes adequately in adults.

While the finding may not apply to every youth with type 2 diabetes, it is a wake-up call for researchers because there is no other FDA-approved medication to treat the disease in young people. The lack of effectiveness may be due to the more aggressive nature of the disease in youth.

Principal investigator Sonia Caprio said, “The incidence of type 2 diabetes is rising in adolescents. Yet we are in a very poor position because we don’t know how best to treat it. Newer medications that target insulin sensitivity, or resistance to insulin, in youth may be needed.”

Read the study, and additional RISE research, published in Diabetes Care.